S&P 500   4,286.27 (-1.18%)
DOW   33,677.19 (-0.97%)
QQQ   355.08 (-1.26%)
AAPL   172.73 (-1.90%)
MSFT   311.25 (-1.98%)
META   298.36 (-0.82%)
GOOGL   127.41 (-2.82%)
AMZN   127.02 (-3.24%)
TSLA   247.43 (+0.18%)
NVDA   422.20 (+0.00%)
NIO   8.54 (+2.28%)
BABA   86.24 (-1.12%)
AMD   96.33 (-1.08%)
T   14.97 (-0.60%)
F   12.51 (-0.56%)
MU   68.56 (-0.03%)
CGC   0.97 (+2.87%)
GE   110.24 (-1.32%)
DIS   80.31 (-0.86%)
AMC   8.27 (+1.60%)
PFE   32.68 (-0.91%)
PYPL   58.98 (+0.20%)
NFLX   383.51 (-0.34%)
S&P 500   4,286.27 (-1.18%)
DOW   33,677.19 (-0.97%)
QQQ   355.08 (-1.26%)
AAPL   172.73 (-1.90%)
MSFT   311.25 (-1.98%)
META   298.36 (-0.82%)
GOOGL   127.41 (-2.82%)
AMZN   127.02 (-3.24%)
TSLA   247.43 (+0.18%)
NVDA   422.20 (+0.00%)
NIO   8.54 (+2.28%)
BABA   86.24 (-1.12%)
AMD   96.33 (-1.08%)
T   14.97 (-0.60%)
F   12.51 (-0.56%)
MU   68.56 (-0.03%)
CGC   0.97 (+2.87%)
GE   110.24 (-1.32%)
DIS   80.31 (-0.86%)
AMC   8.27 (+1.60%)
PFE   32.68 (-0.91%)
PYPL   58.98 (+0.20%)
NFLX   383.51 (-0.34%)
S&P 500   4,286.27 (-1.18%)
DOW   33,677.19 (-0.97%)
QQQ   355.08 (-1.26%)
AAPL   172.73 (-1.90%)
MSFT   311.25 (-1.98%)
META   298.36 (-0.82%)
GOOGL   127.41 (-2.82%)
AMZN   127.02 (-3.24%)
TSLA   247.43 (+0.18%)
NVDA   422.20 (+0.00%)
NIO   8.54 (+2.28%)
BABA   86.24 (-1.12%)
AMD   96.33 (-1.08%)
T   14.97 (-0.60%)
F   12.51 (-0.56%)
MU   68.56 (-0.03%)
CGC   0.97 (+2.87%)
GE   110.24 (-1.32%)
DIS   80.31 (-0.86%)
AMC   8.27 (+1.60%)
PFE   32.68 (-0.91%)
PYPL   58.98 (+0.20%)
NFLX   383.51 (-0.34%)
S&P 500   4,286.27 (-1.18%)
DOW   33,677.19 (-0.97%)
QQQ   355.08 (-1.26%)
AAPL   172.73 (-1.90%)
MSFT   311.25 (-1.98%)
META   298.36 (-0.82%)
GOOGL   127.41 (-2.82%)
AMZN   127.02 (-3.24%)
TSLA   247.43 (+0.18%)
NVDA   422.20 (+0.00%)
NIO   8.54 (+2.28%)
BABA   86.24 (-1.12%)
AMD   96.33 (-1.08%)
T   14.97 (-0.60%)
F   12.51 (-0.56%)
MU   68.56 (-0.03%)
CGC   0.97 (+2.87%)
GE   110.24 (-1.32%)
DIS   80.31 (-0.86%)
AMC   8.27 (+1.60%)
PFE   32.68 (-0.91%)
PYPL   58.98 (+0.20%)
NFLX   383.51 (-0.34%)
NASDAQ:CELC

Celcuity (CELC) Stock Forecast, Price & News

$9.80
+0.23 (+2.40%)
(As of 11:28 AM ET)
Compare
Today's Range
$9.51
$10.14
50-Day Range
$8.96
$10.75
52-Week Range
$7.50
$14.40
Volume
6,042 shs
Average Volume
76,624 shs
Market Capitalization
$216.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

Celcuity MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
161.2% Upside
$25.00 Price Target
Short Interest
Bearish
26.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Celcuity in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$6,194 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.77) to ($2.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

608th out of 961 stocks

Medical Laboratories Industry

15th out of 23 stocks


CELC stock logo

About Celcuity (NASDAQ:CELC) Stock

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

CELC Price History

CELC Stock News Headlines

Will Celcuity's VIKTORIA-1 Hit The Target?
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Celcuity to Host Virtual Science Day for Investors
Celcuity (CELC) Has a New Rating from Craig-Hallum
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Q2 2023 Celcuity Inc Earnings Call
Celcuity Set to Join Russell 2000 and 3000 Indexes
Q1 2023 Celcuity Inc Earnings Call
Craig-Hallum Keeps Their Buy Rating on Celcuity (CELC)
A Preview Of Celcuity's Earnings
See More Headlines
Receive CELC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter.

CELC Company Calendar

Last Earnings
8/10/2023
Today
9/26/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CELC
Fax
N/A
Employees
45
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+161.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-40,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.17 per share

Miscellaneous

Free Float
16,724,000
Market Cap
$211.40 million
Optionable
Not Optionable
Beta
0.60
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Brian F. Sullivan (Age 61)
    Co-Founder, Chairman & CEO
    Comp: $105.77k
  • Dr. Lance G. Laing Ph.D. (Age 61)
    Co-Founder, Chief Science Officer, VP, Sec. & Director
    Comp: $325.38k
  • Ms. Vicky Hahne (Age 57)
    Chief Financial Officer
    Comp: $210k
  • Dr. John R. MacDonald Dabt (Age 68)
    Ph., Ph.D., Sr. VP of R&D
  • Ms. Sheri Smith
    Acting Head of Clinical Operations
  • Mr. Igor Gorbatchevsky M.D.
    Chief Medical Officer













CELC Stock - Frequently Asked Questions

Should I buy or sell Celcuity stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CELC shares.
View CELC analyst ratings
or view top-rated stocks.

What is Celcuity's stock price forecast for 2023?

1 equities research analysts have issued 1 year target prices for Celcuity's stock. Their CELC share price forecasts range from $25.00 to $25.00. On average, they anticipate the company's share price to reach $25.00 in the next year. This suggests a possible upside of 161.2% from the stock's current price.
View analysts price targets for CELC
or view top-rated stocks among Wall Street analysts.

How have CELC shares performed in 2023?

Celcuity's stock was trading at $14.01 on January 1st, 2023. Since then, CELC shares have decreased by 31.7% and is now trading at $9.57.
View the best growth stocks for 2023 here
.

When is Celcuity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our CELC earnings forecast
.

How were Celcuity's earnings last quarter?

Celcuity Inc. (NASDAQ:CELC) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.01.

What other stocks do shareholders of Celcuity own?
When did Celcuity IPO?

(CELC) raised $18 million in an initial public offering on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

What is Celcuity's stock symbol?

Celcuity trades on the NASDAQ under the ticker symbol "CELC."

Who are Celcuity's major shareholders?

Celcuity's stock is owned by a number of retail and institutional investors. Top institutional investors include Commodore Capital LP (6.66%), BlackRock Inc. (4.21%), Captrust Financial Advisors (2.57%), Geode Capital Management LLC (1.36%), State Street Corp (1.21%) and Northern Trust Corp (0.84%). Insiders that own company stock include Brian F Sullivan, Richard E Buller and Richard Nigon.
View institutional ownership trends
.

How do I buy shares of Celcuity?

Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celcuity's stock price today?

One share of CELC stock can currently be purchased for approximately $9.57.

How much money does Celcuity make?

Celcuity (NASDAQ:CELC) has a market capitalization of $211.40 million. The company earns $-40,370,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis.

How can I contact Celcuity?

Celcuity's mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The official website for the company is www.celcuity.com. The company can be reached via phone at (763) 392-0767.

This page (NASDAQ:CELC) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -